CCEP's €2.17 H1 EPS Says the Machine Is Running-But 4.4% Revenue Growth Is the Real Test

CCEP's first half: profit strength is clear, demand durability is the question

CCEP's €2.17 diluted H1 EPS shows an operating engine that is still converting a modest top-line base into a stronger profit outcome. But the more important durability signal is revenue.

On a €10.724B H1 revenue base, CCEP produced €1.458B operating profit and €2.17 diluted EPS, with 9.1% H1 EPS growth. Improved margins show resilience; 4.4% H1 revenue growth is what suggests demand is still expanding rather than merely holding up.

That distinction matters because the Q1 setup was partly helped by timing. In Q1, CCEP posted €5.0B in revenue, and management said stronger volumes benefited from calendar phasing and an earlier Easter. That does not diminish execution, but it does mean part of the early lift was timing rather than pure underlying momentum.

By the half-year mark, the scoreboard is clearer. The next test is whether this was the beginning of a durable run rather than an unusually favorable first half.

Volume, pricing, and profit all improved together

The H1 mix was not dependent on one driver

The positive part of the story is that H1 was not built on a single lever. CCEP posted 5.6% H1 comparable volume growth alongside 0.4% revenue per unit case growth, while comparable operating profit rose 6.5%. In other words, the business was not leaning only on price and not only on volume.

For a bottler, that mix usually matters. When volume and pricing both move higher, it often points to a combination of consumer demand and channel relevance.

Why the Q1-to-H1 transition matters to investors

Bulls will focus on the shift from Q1 to the full half. In Q1, revenue rose 9.4% on a comparable FX-neutral basis, but comparable volume was 1.6%. That made Q1 look more calendar-sensitive than a clean momentum read.

By the half, the picture looked more balanced. The key question now is whether CCEP can preserve a meaningful share of that H1 volume in H2 without calendar support. If it can, the full-year operating-leverage story remains credible.

The main watchpoint: protect the demand signal

Skeptics will still argue that revenue per unit case must not do too much of the work over time. If pricing does increasing portions of the lifting, the story looks more like a margin exercise than a demand story.

There is also a known headwind to absorb. Management flagged the Suntory alcohol exit at roughly a 0.5% FY revenue impact. That is not large, but it removes a cushion in H2 and leaves less room for error elsewhere.

The next update is really a guidance test

The durability test now shifts from the half itself to what management can still defend. After a strong first half, the key question is whether CCEP still sounds credible while reaffirming ~7% FY26 operating profit growth, ≥€1.7B comparable free cash flow, and a €0.82 interim dividend per share.

Investors are no longer paying only for a quarter shaped by calendar phasing and an earlier Easter. They are paying for a second half that has to stand on its own.

What to watch in the next update

• Volume: does it stay positive without calendar help?
• Revenue per unit case: does it remain non-negative, indicating pricing power is not breaking?
• Profit versus revenue: does profit growth continue to outrun revenue growth, supporting the full-year operating-profit guide?
• Cash flow: does performance remain consistent with the ≥€1.7B comparable free cash-flow target?

The practical takeaway is simple: treat CCEP as a quality name that now needs confirmation, not as a momentum trade. A strong first half can still lead to a strong year, but the next update matters more because it will show how much of the early strength was durable.